<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347474">
  <stage>Registered</stage>
  <submitdate>16/09/2011</submitdate>
  <approvaldate>27/09/2011</approvaldate>
  <actrnumber>ACTRN12611001026910</actrnumber>
  <trial_identification>
    <studytitle>SOURCE ANZ - An observational study using registry data to assess safety and efficacy outcomes data in patients with diagnosed Aortic Valve Stenosis who may be eligible for replacing the aortic heart valve without the need for open heart surgery</studytitle>
    <scientifictitle>Edwards SAPIEN Transcatheter Heart Valve Australian and New Zealand SOURCE Registry: A multi-centre Observational Registry of Percutaneous Aortic Valve Replacement (PAVR) using the Edwards SAPIEN Transcatheter Heart Valve to collect the safety and efficacy outcomes data.</scientifictitle>
    <utrn />
    <trialacronym>SOURCE</trialacronym>
    <secondaryid>SOURCE Registry # 2008-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe Aortic Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with severe Aortic Stenosis may be eligible for the insertion of a biological heart valve implanted percutaneously via the transfemoral or transapical route then balloon expanded once in the aortic valve position.
The SOURCE registry is a database documenting patient outcomes at 30 days and 12 months post procedure. 
The data extracted measures procedure success and quality of life improvement. Also measured are the major complications associated with the procedure and device.</interventions>
    <comparator>No treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and efficacy measured by procedural success at 30 days</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Collect the safety and efficacy outcomes data of the patients who received the Edwards SAPIEN Valve for the treatment of calcific dengenerative aortic stenosis.</outcome>
      <timepoint>Hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Collect the safety and efficacy outcomes data of the patients who received the Edwards SAPIEN Valve for the treatment of calcific dengenerative aortic stenosis</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key inclusion critieria  
1. Aortic valve area &lt;0.8 cm2
2. Patients with symptomatic, severe calcific degenerative aortic stenosis requiring AVR, and considered to have high risk of operative mortality or is non-operable.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Key Exclusion criteria  
1. Patients with non-valvular, non-calcific acquired or congenital aortic stenosis, with unicuspid or bicuspid aortic valve 
2. Patients unsuitable for AVR via transfemoral or transapical approach</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>8/12/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>133</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4064</postcode>
    <postcode>2010</postcode>
    <postcode>2305</postcode>
    <postcode>2031</postcode>
    <postcode>2065</postcode>
    <postcode>5042</postcode>
    <postcode>6000</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Edwards Lifesciences Pty Ltd</primarysponsorname>
    <primarysponsoraddress>8/167 Prospect Highway
Seven Hills NSW 2147</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Prince Charles Hospital</fundingname>
      <fundingaddress>Rode Road
Chermside QLD 4064</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital</ethicname>
      <ethicaddress>Rode Road
Chermside QLD 4064</ethicaddress>
      <ethicapprovaldate>11/02/2010</ethicapprovaldate>
      <hrec>HREC/09/QCPH/177</hrec>
      <ethicsubmitdate>23/10/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Sydney Human Research and Ethics Committee</ethicname>
      <ethicaddress>390 Victoria Street
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>21/05/2009</ethicapprovaldate>
      <hrec>HREC/08/SVH/178</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter Area Health Service Human Research and Ethics Committee</ethicname>
      <ethicaddress>Lookout Road
New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>23/04/2010</ethicapprovaldate>
      <hrec>HREC/09/SVH/178</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South Eastern Sydney Health Service Human Research and Ethics Committee</ethicname>
      <ethicaddress>Barker Street
Randwick NSW 2031</ethicaddress>
      <ethicapprovaldate>9/06/2010</ethicapprovaldate>
      <hrec>08/SVH/178</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Sydney Area Health Service Royal North Shore Hospital</ethicname>
      <ethicaddress>Pacific Highway
St Leonards NSW 2065</ethicaddress>
      <ethicapprovaldate>3/05/2010</ethicapprovaldate>
      <hrec>08/SVH/178</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Flinders Drive
Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate>11/12/2008</ethicapprovaldate>
      <hrec>1/08/0258</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Human Research and Ethics Committee</ethicname>
      <ethicaddress>Wellington Street
Perth WA 6000</ethicaddress>
      <ethicapprovaldate>7/04/2009</ethicapprovaldate>
      <hrec>TGA 2OO9.01</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Meryl Musson</name>
      <address>8/167 Prospect Highway
Seven Hills NSW 2147</address>
      <phone>+61 2 8811 2604</phone>
      <fax>+61 2 8811 2614</fax>
      <email>meryl_musson@edwards.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Meryl Musson</name>
      <address>8/167 Prospect Highway
Seven Hills NSW 2147</address>
      <phone>+61 2 8811 2604</phone>
      <fax>+61 2 8811 2614</fax>
      <email>meryl_musson@edwards.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Meryl Musson</name>
      <address>8/167 Prospect Highway 
Seven Hills NSW 2147</address>
      <phone>+61 2 8811 2604</phone>
      <fax>+61 2 8811 2614</fax>
      <email>meryl_musson@edwards.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>